

Fall Group Meeting

Chicago Specials

SEPTEMBER 18-20, 2025

Barlogie-Salmon Myeloma Committee

Barlogie-Salmon Myeloma Committee

Leadership

Chair: Robert Z. Orlowski, MD, PhD
 Vice-Chair: Sikander Ailawadhi, MD
 Vice-Chair: Jing Christine Ye, MD, MSc
 Executive Officer: Susan M. O'Brien, MD
 Statisticians: Antje Hoering, PhD
 Rachael Sexton, MS
 Adam Rosenthal, MS
 Sara Threlkel, BS

Scientific Leadership

Translational Medicine: Brian A. Walker, BSc, PhD
 Radiation: Chelsea Camille Pinnix, MD, PhD
 Surgery: TBD
 Imaging: Eric M. Rohren, MD, PhD
 Pathology: Pei Lin, MD
 Early Therapeutics: Frits van Rhee, MD, PhD

Designates

NCORP Representative: Charles S. Kuzma, MD
 Veterans Affairs: Thomas R. Chauncey, MD, PhD
 Data Coordinators: Aubrey Gilmore, BA
 Daria Chugina, MD, CCRPS
 Pasarlai Ahmadzai, MD, MPH
 Oncology Research Professionals:
 CRA: Brandon Richard Labadie, CCRP
 Nurse: TBD
 Patient Advocate: Paul Gater, MPhil
 Pharmaceutical Science: Craig Elg, PharmD
 Ila M. Saunders, PharmD
 Protocol Project Manager: Amy Doyle
 Clinical Trials Program Manager: Sharon Palmer

Time/Location

Saturday, September 20, 2025 12:00 p.m. - 2:00 p.m.
 Room: Comiskey (Concourse Level, West Tower)

Active Studies

S2005, "A Phase II Randomized Study Comparing Ibrutinib and Rituximab vs. Venetoclax and Rituximab in Previously Untreated Waldenström's Macroglobulinemia (WM) / Lymphoplasmacytic Lymphoma (LPL)" Drs. S. Ailawadhi and D. Bhutani. Activated: 6/24/21; Closed: 4/8/22; Re-activated: 2/15/24.

S2209, "A Phase III Randomized Trial for Newly Diagnosed Multiple Myeloma (NDMM) Patients Considered Frail or Ineligible for Stem

Cell Transplant Comparing Upfront Bortezomib-Lenalidomide-Dexamethasone-Lite (VRd-Lite) with Daratumumab-Lenalidomide-Dexamethasone (DRd)." Drs. S. Ailawadhi, J.C. Ye, B. Lipe, T. Chauncey, and K. Gowin. Activated 5/30/23.

S2213, "Daratumumab, Cyclophosphamide, Bortezomib, and Dexamethasone (D-VCD) Induction Followed by Autologous Stem Cell Transplant or D-VCD Consolidation and Daratumumab Maintenance in Patients with Newly Diagnosed AL Amyloidosis." Drs. P. Hagen, T. Parker, and S. Sidana. Activated 12/1/23.

A062102, "Randomized Phase II Study of Ixerdomide Maintenance Therapy Following Idecabtagene Vicleucel CAR-T in Multiple Myeloma Patients." Dr. R. Banerjee. Activated: 4/4/24.

EEA173, "Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma." Dr. E. Manasanch. Activated: 4/30/19.

EEA181, "Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial." Dr. K. Gowin. Activated: 10/27/20.

Developing Studies

S2508, "A Phase II Study of Optimal Induction and MRD Driven Maintenance Therapy for Patients with Newly Diagnosed High-Risk Multiple Myeloma (HRMM)." Drs. B. Lipe, J.C. Ye, and A. Cowan.

Closed Studies

S1803, "Phase III Study of Daratumumab/rHuPH20 (NSC-810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)." Drs. A. Krishnan and S. Chhabra. Activated: 6/27/19. Registration Step 1 Closed to Accrual: 1/15/25.

S1211, "A Randomized Phase I/II Study of Optimal Induction Therapy of Bortezomib, Dexamethasone and Lenalidomide with or Without Elotuzumab (NSC-764479) for Newly Diagnosed High Risk Multiple Myeloma (HRMM)." Drs. S. Usmani, S. Ailawadhi, and B. Lipe. Activated: 11/9/12. Closed: 6/2/16.

S1702, "A Phase II Study of Isatuximab (SAR650984) (NSC-795145) for Patients with Previously Treated AL Amyloidosis." Drs. T. Parker and V. Sanchirawala. Activated: 3/8/18; Closed: 9/30/19.

S1304, "A Phase II Randomized Study Comparing Two Doses of Carfilzomib with Dexamethasone for Relapse/Refractory Multiple Myeloma." Dr. S.

Barlogie-Salmon Myeloma Committee

Ailawadhi. Activated: 10/18/13. Closed: 11/6/15; Complete: 1/17/25.

S0777, "Frontline Phase III Rev/Dex +/- Vel, no upfront transplant." Dr. B. Durie. Activated: 4/1/18. Closed: 2/2/12.

S0120, "A prospective Observational Biologic Study of Asymptomatic Patients with Monoclonal Gammopathy and Plasmaproliferative Disorders." Dr. M. Dhodapkar. Activated: 6/1/02. Closed: 4/1/11.

CTN 0702, "Single Autologous Transplant with or without RVD Consolidation versus Tandem Transplant and Maintenance Therapy." Dr. G. Somlo. Activated: 2/15/11. Closed: 11/15/13.

A061402, "Ixazomib Citrate, Lenalidomide, Dexamethasone, and Zoledronic Acid or Zoledronic Acid Alone after Radiation Therapy in Treating Patients with Solitary Plasmacytoma of Bone." Dr. A. Kuman Mahindra. Activated: 12/23/15. Closed: 8/15/19.

E1A11, "Randomized Phase III Trial of Bortezomib, LENalidomide and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide and Dexamethasone (CRd) Followed by Limited or Indefinite DURation Lenalidomide MaintenANCE in Patients with Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)." Drs. S. Kumar, A. Cohen, and J. Zonder. Activated: 11/22/13. Closed: 1/29/19.

E3A06 (was S0909), "High-risk AMM – Revlimid." Dr. M. Dhodopkar. Activated: 1/17/11. Closed: 7/14/17.

A061402, "Ixazomib Citrate, Lenalidomide, Dexamethasone, and Zoledronic Acid or Zoledronic Acid Alone after Radiation Therapy in Treating Patients with Solitary Plasmacytoma of Bone." Dr. A. Kumar Mahindra. Activated: 12/23/15. Closed: 8/15/19.

EAA171, "Optimizing Prolonged Treatment in Myeloma Using MRD Assessment (OPTIMUM)." Dr. S. Kumar. Activated: 6/1/21. Closed 3/3/23.

Proposed Studies-Pre-Triage/On Hold

SXXXX, "A Phase III Study for Evaluation of Maintenance Cessation in Patients with Standard Risk Myeloma Achieving Minimal Residual Disease Negativity." Dr. M. Mohyuddin.

SXXXX, "A Phase II Trial of BCMA Bi-Specific T-Cell Engager (BiTE) Teclistamab in Patients with Systemic Light Chain (AL) Amyloidosis." Drs. D. Bhutani and K. Dorritie.

SXXXX, "An Open-Label Randomized Phase 2 Trial to Incorporate Venetoclax in Early Relapsed t(11;14) Multiple Myeloma." Dr. R. Chakraborty.

SXXXX, "Developing Smoldering Multiple Myeloma Concept." Drs. P. Hagen and A. Cowan.

Publications

The publications listed below were received by the Group Chair's Office as published (including online), accepted, or submitted since the SWOG Spring 2025 Group Meeting. Conference abstracts are not included.

Because of journal embargo policies, journal names are omitted for submitted or accepted manuscripts.

Published/Accepted Manuscripts

None this cycle

Submitted Manuscripts

S1702 Isatuximab in Relapsed AL Amyloidosis: Results of a Prospective Phase II Trial. Parker T, Rosenthal A, Sanchorawala V, Landau H, Campagnaro E, Kapoor P, Neparidze N, Girmius S, Hagen P, Scott E, Hoering A, Durie B, Orlowski R. (SWOG S1702). Submitted 2025.

Barlogie-Salmon Myeloma Committee

Accrual from trials that are open as of 6/30/2025 or have closed in the prior 18 months, by Institution and Study

	<i>S1803</i>	<i>S2005</i>	<i>S2209</i>	<i>S2213</i>	<i>EAA173</i>	<i>EAA181</i>
AdventHealth Parker	2	-	-	-	-	-
Banner University Medical Center - Tucson	12	-	-	-	-	5
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center	-	-	2	-	-	-
Boston Medical Center	5	-	-	2	-	-
CWRU Case Comprehensive Cancer Center LAPS	28	-	-	-	8	-
Cancer Research for the Ozarks NCORP	2	-	-	-	-	-
Cancer Research of Wisconsin and Northern Michigan Consortium	5	-	-	-	-	-
Carle Cancer Center NCI Community Oncology Research Program	-	-	2	-	-	-
Cedars-Sinai Medical Center	6	-	-	-	-	-
City of Hope Comprehensive Cancer Center	118	-	3	-	-	-
Columbia University Minority Underserved NCORP	-	-	1	3	-	-
Columbus NCI Community Oncology Research Program	5	-	-	-	-	-
CommonSpirit Health Research Institute	1	-	3	-	-	-
Dayton NCI Community Oncology Research Program	5	-	-	-	-	-
Duke University - Duke Cancer Institute LAPS	3	-	-	2	-	-
Essentia Health NCI Community Oncology Research Program	-	-	1	-	-	-
Fred Hutchinson Cancer Research Center LAPS	7	-	-	-	8	-
Froedtert and the Medical College of Wisconsin LAPS	12	-	-	-	-	-
Georgia NCI Community Oncology Research Program	21	-	-	-	-	-
Gulf South Minority Underserved NCORP	4	-	-	-	-	-
Heartland Cancer Research NCORP	12	-	4	-	-	-
Henry Ford Health Providence Southfield Hospital	2	-	-	-	1	1
Henry Ford Hospital	-	-	-	-	2	-
Houston Methodist Hospital	13	-	-	-	-	-
Kaiser Permanente NCI Community Oncology Research Program	60	-	7	-	-	-
Kansas City Veterans Affairs Medical Center	-	-	4	-	-	-
Lahey Hospital and Medical Center	3	-	-	-	-	-
Loyola University Medical Center	26	-	-	-	3	3
MU Health Care Goldschmidt Cancer Center	3	-	-	-	-	-
Massachusetts Veterans Epidemiology Research and Information Center	-	-	1	-	-	2
Medical University of South Carolina Minority Underserved NCORP	60	-	-	-	1	1
Mercy Medical Center - Des Moines	1	-	-	-	-	-
Michigan Cancer Research Consortium NCORP	13	-	1	-	-	-
Moffitt Cancer Center	48	-	-	-	-	-

Barlogie-Salmon Myeloma Committee

Accrual from trials that are open as of 6/30/2025 or have closed in the prior 18 months, by Institution and Study

	<i>S1803</i>	<i>S2005</i>	<i>S2209</i>	<i>S2213</i>	<i>EAA173</i>	<i>EAA181</i>
Montana Cancer Consortium NCORP	1	-	-	-	-	-
NCORP of the Carolinas (Prisma Health NCORP)	-	-	2	-	-	-
Nevada Cancer Research Foundation NCORP	-	-	-	-	1	-
New Mexico Minority Underserved NCORP	15	-	4	-	-	-
Ohio State University Comprehensive Cancer Center LAPS	5	-	-	-	-	-
Oregon Health and Science University	33	-	1	-	3	9
Pacific Cancer Research Consortium NCORP	18	-	6	1	-	-
Regents of the University of Michigan	16	-	-	-	-	-
Riverside Methodist Hospital	3	-	-	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	3	-	-	-	-	-
Stanford Cancer Institute Palo Alto	-	-	2	-	-	-
Tulane University School of Medicine	-	-	-	-	2	-
UC Davis Comprehensive Cancer Center LAPS	27	-	7	-	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	19	-	-	-	-	-
University of Arkansas for Medical Sciences	-	-	4	-	-	5
University of Cincinnati Cancer Center-UC Medical Center	-	-	-	-	-	2
University of Kansas Cancer Center - MCA Rural MU NCORP	35	-	-	1	-	-
University of Kentucky/Markey Cancer Center	4	-	-	-	-	-
University of Oklahoma Health Sciences Center LAPS	3	-	-	-	-	-
University of Rochester LAPS	15	2	2	-	-	3
University of Texas Health Science Center at San Antonio	23	1	-	-	-	-
University of Texas MD Anderson Cancer Center LAPS	27	-	1	1	-	-
University of Utah - Huntsman Cancer Institute LAPS	16	-	-	-	4	2
Upstate Carolina Consortium Community Oncology Research Program	4	-	-	-	-	-
Vanderbilt University - Ingram Cancer Center LAPS	1	-	-	-	-	-
Wayne State University - Karmanos Cancer Institute LAPS	18	-	2	-	-	-
Wisconsin NCI Community Oncology Research Program	23	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	-	-	4	1	4	8
ALLIANCE	226	2	10	2	-	-
CCTG	21	-	-	-	-	-
ECOG-ACRIN	188	9	6	1	-	-
NRG	116	1	5	-	-	-
Total	1,337	15	85	14	37	41

